Toolkit/endometrial receptivity assay

endometrial receptivity assay

Assay Method·Research·Since 2022

Also known as: ERA

Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

The endometrial receptivity assay (ERA) is a clinical assay intended to assess endometrial receptivity during the window of implantation. The supplied evidence indicates that, as a current test of the window of implantation, it does not consistently improve clinical outcomes measured by live birth rates.

Usefulness & Problems

Why this is useful

ERA is used to evaluate the window of implantation and endometrial receptivity in a clinical reproductive medicine context. However, the supplied evidence states that current tests of the window of implantation, including ERA, do not consistently improve live birth outcomes.

Problem solved

ERA is intended to address the problem of identifying whether the endometrium is receptive during the window of implantation. The supplied evidence also indicates that the biological basis of current clinical markers or tests of the window of implantation is poor.

Taxonomy & Function

Primary hierarchy

Technique Branch

Method: A concrete measurement method used to characterize an engineered system.

Mechanisms

No mechanism tags yet.

Target processes

No target processes tagged yet.

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

The supplied evidence identifies ERA as a clinical assay for assessing endometrial receptivity during the window of implantation. No further implementation details, such as sample type, molecular readout, workflow, or required instrumentation, are provided in the supplied evidence.

The biological basis of current clinical markers or tests of the window of implantation is described as poor. In addition, current tests of the window of implantation, including ERA, do not consistently improve clinical outcomes as measured by live birth rates.

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 2biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 3biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 4biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 5biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 6biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 7biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 8biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 9biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 10biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 11biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 12biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 13biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 14biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 15biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 16biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 17biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 18biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 19biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 20biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 21biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 22biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 23biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 24biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 25biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 26biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 27biological rationale limitationsupports2022Source 1needs review

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.
Claim 28clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 29clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 30clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 31clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 32clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 33clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 34clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 35clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 36clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 37clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 38clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 39clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 40clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 41clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 42clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 43clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 44clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 45clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 46clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 47clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 48clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 49clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 50clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 51clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 52clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 53clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.
Claim 54clinical utility limitationsupports2022Source 1needs review

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.

Approval Evidence

1 source2 linked approval claimsfirst-pass slug endometrial-receptivity-assay
Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.

Source:

biological rationale limitationsupports

The biological basis of current clinical markers or tests of the window of implantation is poor.

The biological basis of current clinical markers or tests of window of implantation is poor.

Source:

clinical utility limitationsupports

Current tests of the window of implantation, including endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes measured by live birth rates.

Current tests of the window of implantation, such as endometrial thickness measurements and the endometrial receptivity assay, do not consistently improve clinical outcomes as measured by live birth rates.

Source:

Comparisons

Source-backed strengths

The available evidence supports that ERA is specifically positioned as a test of endometrial receptivity during the window of implantation. No validated strength in improving live birth rates is supported by the supplied evidence.

endometrial receptivity assay and Field-domain rapid-scan EPR at 240 GHz address a similar problem space.

Shared frame: same top-level item type

endometrial receptivity assay and fluorescence line narrowing address a similar problem space.

Shared frame: same top-level item type

endometrial receptivity assay and native green gel system address a similar problem space.

Shared frame: same top-level item type

Strengths here: looks easier to implement in practice.

Ranked Citations

  1. 1.
    StructuralSource 1Frontiers in Reproductive Health2022Claim 21Claim 22Claim 21

    Seeded from load plan for claim c2. Extracted from this source document.